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Objective: Allograft heart valves are commonly used in cardiac surgery. Despite
mounting evidence that these valves are immunogenic, leading to premature failure,
current clinical practice does not attempt to minimize or control such a response.
The objective of this study was to evaluate immune modulatory approaches to ame-
liorate allograft valve failure in a rat model.
Method: Aortic valve grafts were implanted infrarenally into Lewis rat recipients (n
= 32). There were 4 transplant groups: syngeneic grafts (Lewis to Lewis), untreat-
ed allografts (Brown Norway to Lewis), allograft recipients treated with
cyclosporine (INN: ciclosporin) (10 mg/kg per day for 7 or 28 days), and allograft
recipients treated with anti-α4 integrin and anti-β2 integrin monoclonal antibodies
for 7 days. At 7 and 28 days the valves were examined for structural integrity and
cellular infiltration.
Results: Both cyclosporine and anti-α4/β2 integrin treatment resulted in significant
reduction in leaflet infiltration by macrophages (ED1+), T cells (CD3+), and CD8+
T cells at 7 days with preservation of structural integrity when compared with con-
trol allografts. Twenty-eight days after implantation, daily treatment with
cyclosporine preserved leaflet structural integrity and inhibited cellular infiltration.
However, a short course of cyclosporine (7 days) failed to prevent destruction of the
valves at 28 days.
Conclusions: Immune modulatory approaches aimed at T-cell activation or traffick-
ing decrease leaflet cellular infiltration and prevent allograft valve structural failure.
However, short-course therapy does not appear to be sufficient and must be main-
tained to allow long-term preservation of leaflet structural integrity (28 days).
Thirty-five years after the first cardiac valve replacements were under-taken, a perfect valve substitute has not been developed. Allograftheart valves (homografts) were introduced for aortic valve replace-ment in 19621 and for reconstruction of the right ventricular outflowtract in 1966.2 Allograft valves have many advantages over commer-cially available mechanical and bioprosthetic valves: low trans-
valvular gradients, low rates of thromboembolism, and resistance to infection.3
They are used extensively for children, who are prone to rapid calcification of
xenograft valves and for whom warfarin treatment is difficult.
Despite these advantages, allografts do ultimately fail in the aortic position. In
children aged less than 3 years, allograft failure may be as high as 70% with a mean
replacement interval of 1.9 years after the original operation.4 Proposed causes of
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this failure have included immune rejection. Donor-specific
immune responses to fresh aortic valve grafts have been
shown in animal models.5 Mixed lymphocyte cultures using
spleen cells from allografted rodents have demonstrated a
significant increase in stimulation, suggesting systemic acti-
vation of CD4+ T cells during the initial exposure to the
allograft valve. Further, the frequency of cytotoxic T-lym-
phocyte precursors was significantly increased in the spleen
of these animals. In human beings, some evidence supports
similar cell-mediated responses to allografted valves.6,7 In
particular, there is an accelerated peripheral T-cell response,
specific to donor peripheral blood mononuclear cells, as
demonstrated in recipients of valve grafts 10 days after
implantation, with a peak response appearing on day 30. In
addition, allografts that undergo accelerated failure have
shown evidence of associated T-cell infiltration.8
However, despite mounting evidence that aortic allografts
are immunogenic and can elicit donor-specific immune
responses,9-11 and more particularly T-cell responses,5-8 cur-
rent clinical practice does not attempt to minimize or control
such a response. Some clinicians have attempted to match
valves for ABO blood group compatibility, but there is no evi-
dence that this is beneficial.12 Currently, HLA matching is not
being attempted in patients. Immunosuppressive or anti-
inflammatory agents have occasionally been tried, but no rig-
orous, prospective study has been performed.4
Evidence from animal models suggests that immunosup-
pressive regimens (cyclosporine [INN: ciclosporin]) may
ameliorate humoral responses to valve allografts. However,
no information has been presented regarding the structure of
valve leaflets in such animals nor have any in situ descrip-
tions of the cellular responses been presented.13 We14 have
recently shown that CD3+/CD8+ cytotoxic T lymphocytes
infiltrate allogeneic valve leaflets early after implantation
and that this is associated with structural failure and destruc-
tion of valve leaflets. This infiltration was confirmed by
demonstrating that cellular infiltration and valve destruction
do not occur in the absence of a functional T-cell compart-
ment (nude rat recipients).14
T-lymphocyte trafficking to transplanted organs remains
poorly studied, with most of the work having been per-
formed in models of acute and chronic inflammation. On
the basis of these models, lymphocytes are believed to infil-
trate organs by adhesion to vascular endothelial cells using
cell adhesion molecules (CAMs), with subsequent transmi-
gration through the endothelium.15 Alpha 4 (α4) and beta 2
(β2) integrin molecules appear particularly important for the
trafficking of T lymphocytes because the expression of their
respective ligands has been shown to be up-regulated on
vascular endothelial and parenchymal cells of transplanted
organs, including valve grafts, early in the rejection
process.15-17 The identification of specific CAMs necessary
for mononuclear infiltration of allotransplanted valve
leaflets would provide important mechanistic information
and offer the potential for therapeutic applications.
The objectives of this study were (1) to evaluate the role
of a classic T-cell immunosuppressant (cyclosporine) and
(2) to identify mechanisms by which these T cells infiltrate
leaflets lead to allograft valve failure in a rat model.
Materials and Methods
Animals
Inbred male Brown Norway (RT1.An) and Lewis (RT1.Al) rats
weighing 250 to 350 g were purchased from Harlan Sprague
Dawley, Inc (Indianapolis, Ind) and housed in the Medical
Sciences animal care facility with food and water ad libitum for 1
week before experimentation. The animals were handled in accor-
dance with the guidelines of the Canadian Council of Animal
Care.18
Aortic Valve Allograft Implantation
Transplantation of aortic valve allografts was performed as first
described by Yankah, Wottge, and Muller-Ruchholtz.19 An
intraperitoneal injection of sodium pentobarbital, 65 mg/kg, was
used to anesthetize the rats.
Donor operation. A midline upper abdominal incision was made
and extended as a median sternotomy. The aortic valve containing
some myocardium and approximately 8 mm of ascending aorta was
dissected free, and the coronary ostia were ligated with 9-0 nylon
sutures (Sharpoint, Reading, Pa). The graft was then rinsed with cold
isotonic saline solution. Both the donor and recipient operations were
performed with a Weck OM-1206 mounted operating microscope
(Weck Closure Systems, Research Triangle Park, NC).
TABLE I. Experimental groups (n = 32)
No. No. at No. at 
Group Recipient Donor Treatment transplanted 7 days 28 days
Syngeneic controls Lewis Lewis None 8 4 4
Untreated allogeneic Lewis BN None 8 4 4
Allogeneic + CAM Lewis BN Anti-α4/β2 4 3 —
Allogeneic + CyA Lewis BN Daily CyA × 7 days 8 4 4
Allogeneic + CyA Lewis BN Daily CyA × 28 days 4 — 4
The 5 groups of animals created and treatments received. BN, Brown Norway; CAM, cell adhesion molecule; CyA, cyclosporine.
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Recipient operation. A midline laparotomy was performed, the
bowel eviscerated to the right, and the abdominal aorta exposed. The
aorta was mobilized from the level of the renal artery to the aortic
bifurcation and divided between clamps. The fresh aortic valve allo-
graft was then anastomosed between the stumps of the recipient aorta
with interrupted 9-0 nylon sutures (Sharpoint), being flushed inter-
mittently with heparinized saline solution. Once hemostasis was
secured, the abdominal contents were returned into the peritoneal
cavity and the wound was closed in layers. Strain combinations for
experimentation consisted of syngeneic controls (Lewis to Lewis; n
= 8), untreated allograft recipients (Brown Norway to Lewis; n = 8),
allograft recipients treated with cyclosporine (n = 12), and allograft
recipients treated with anti-α4/β2 monoclonal antibody (mAb) (n =
4). A single animal died after the operation and was part of the anti-
α4/β2 group. Table 1 illustrates the various groups of animals creat-
ed and the treatment received.
Immune Modulation of Recipients
Cyclosporine (Sandoz Canada, Dorval, Quebec, Canada), dosage
10 mg/kg per day diluted in olive oil, was given by gavage feeding
as previously reported.13,20 Random serum cyclosporine levels
measured several days after valve implantation were obtained by
radioimmunoassay (DiaSorin Cyclo-Trac, QEII HSC; DiaSorin,
Inc, Stillwater, Minn) in 2 animals and shown to be 1450 and 1615
µg/L. CAM blockade consisted of the mAb TA-2 (immunoglobu-
lin [Ig] G1 blocking mAb specific for α4 integrin subunit; 3 mg
intravenously) and the mAb WT.3 (IgG1 blocking mAb specific
for CD18 or β2; 3 mg intravenously) given on day 0 and repeated
on day 4 after valve implantation.21,22 Dosing was based on previ-
ous studies documenting antibody serum levels and efficacy of
treatment at blocking cellular trafficking.23,24 The presence of anti-
body in serum was confirmed by flow cytometry (fluorescence-
activated cell sorter staining). Flow cytometry was performed on a
BD FACScan with Lysis II software (Becton Dickinson, Franklin
Lakes, NJ).
Tissue Analysis
Grafts were harvested for histologic examination at 7 and 28 days
and immersion-fixed (10% formaldehyde) at 4˚C for 12 hours.
Grafts were then paraffin-embedded, and 5-µm sections were cut
serially for histologic and immunocytochemical examinations.
Tissue sections were stained with hematoxylin and eosin
(Harris hematoxylin) or Verhoeff elastin stain (hematoxylin 5%,
ferric chloride 10%, and Lugol iodine). Tissue slides from each
animal were then examined with a light microscope and images
digitized and captured (JVC digital camera, model TK1070U;
JVC Professional Products Company, Wayne, NJ).
Morphometric analysis was carried out with Adobe Photoshop
Figure 1. Photomicrographs of valve leaflets 7 days after implantation in syngeneic (Lewis to Lewis) (a), untreat-
ed allograft recipients (Brown Norway to Lewis) (b), allograft recipients treated with anti-α4/β2 monoclonal anti-
body (c), and allograft recipients treated with cyclosporine (d). Arrow indicates leaflet. (Original magnification
×200.)
Légaré et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 2 313
TX
ET
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
Figure 2. Photomicrographs of immunocytochemical staining 7 days after implantation in untreated allograft recip-
ients (Brown Norway to Lewis) anti-ED1 (a) and anti-CD8 (d); allograft recipients treated with anti-α4/β2 mono-
clonal antibody anti-ED1 (b) and anti-CD8 (e); and allograft recipients treated with cyclosporine, anti-ED1 (c) and
anti-CD8 (f), with a secondary immunoperoxidase reaction. Arrow indicates leaflet. (Original magnification ×200.)
Figure 3. Graph comparing the number of immunolabeled cells per surface area present in leaflets 7 days after
implantation in control syngeneic (Lewis to Lewis), untreated allograft recipients (Brown Norway to Lewis), allo-
graft recipients treated with anti-α4/β2, and allograft recipients treated with cyclosporine. The antibodies used
were anti-ED1, anti-CD3, and anti-CD8 monoclonal antibody and secondary immunoperoxidase reaction. Counts
were expressed as number of cells per square millimeter of leaflet area. allo, Allogeneic; CAM, cell adhesion
molecule; syn, syngeneic.
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(Microsoft, Inc, Redmond, Wash) and NIH Image analyzer soft-
ware on a Power PC (G3, Apple Computer, Cupertino, Calif) to
measure surface area (square micrometers) and cell counts per
area. Leaflet cell density (number of labeled cells per area) was
obtained from sampling of the entire leaflet area from represen-
tative tissue cross sections from each animal (area where leaflet
cusps were visualized). Adventitial cell counts were obtained
from the average cell density (number of labeled cells per area)
of 4 representative areas of adventitia sampled at the 0, 3, 6, and
9 o’clock positions from representative tissue cross sections
from each animal.
Immunohistochemistry 
After deparaffinization, endogenous peroxidase was quenched
(0.06% hydrogen peroxide/methanol), nonspecific staining was
blocked with normal horse serum, and sections were subsequently
incubated with primary mAb for 1 hour at 37˚C. The antibodies
used were anti-ED1 (ED1; Cedarlane Laboratories, Hornby,
Ontario, Canada) specific for monocyte/macrophage lineage cells,
anti-CD3 (R73; Cedarlane Laboratories) specific for αβ T-cell
receptor positive bearing cells, and anti-CD8 (MRC OX-8;
Cedarlane Laboratories) specific for a cell surface molecule pre-
sent on CD8+ cytotoxic T lymphocytes. Sections were then washed
in phosphate-buffered saline solution containing 1% bovine serum
albumin (Sigma Chemical Company, St Louis, Mo) 3 times before
incubation with biotinylated secondary antibody and labeling with
peroxidase avidin/biotin complex using 3.3´ diaminobenzidine as
the chromogen (Vector Laboratories, Inc, Burlingame, Calif).
Statistics 
The mean number of cells counted from histologic slides was
obtained from 4 animals in each group. Data were reported as mean
and standard error of the mean. Changes in cellular density were
expressed as percent change between treated and untreated control
animals with syngeneic density counts used as baseline values.
Analysis of variance was used to evaluate groups consisting of syn-
geneic controls, untreated allografts, allografts treated with
cyclosporine, and allografts treated with anti-α4/β2. The post hoc
Fisher test of least significant difference was used to assess statistical
significance with P < .05 being the limit of significance. An unpaired
2-tailed Student t test was used for simple comparisons to assess sta-
tistical significance with  P < .05 being the limit of significance.
Results
Transplanted valve grafts were harvested and evaluated by
light microscopy 7 days after implantation in syngeneic
controls (Lewis to Lewis, n = 4), untreated allograft recipi-
ents (Brown Norway to Lewis, n = 4), allograft recipients
treated with cyclosporine (n = 4), and allograft recipients
treated with anti-α4/β2 (n = 3). Syngeneic control aortic
valve leaflets remained thin, cellular, and showed no evi-
dence of immune infiltration into the leaflets (Figure 1, a).
Allografted aortic valve leaflets exhibited significant
mononuclear cell infiltration (Figure 1, b), as previously
described, when compared with syngeneic controls.10,14
Figure 4. Graph comparing the number of immunolabeled cells per surface area present in the adventitia 7 days
after implantation in control syngeneic (Lewis to Lewis), untreated allograft recipients (Brown Norway to Lewis),
allograft recipients treated with anti-α4/β2, and allograft recipients treated with cyclosporine. The antibodies
used were anti-ED1, anti-CD3, and anti-CD8 monoclonal antibody and secondary immunoperoxidase reaction.
Counts were expressed as number of cells per square millimeter area of adventitia obtained from multiple sam-
pled areas. allo, Allogeneic; CAM, cell adhesion molecule; syn, syngeneic.
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Cyclosporine therapy resulted in significantly less
mononuclear cell infiltration of both valve leaflets and
adventitia with preservation of structural leaflet integrity at 7
days (Figure 1, d). Immunocytochemistry was used to quan-
titate and characterize the nature of immune infiltrating cells
7 days after implantation (Figures 2, 3, and 4). There was a
98% (P = .005) reduction in ED1+ cells, 100% (P ≤ .001)
reduction in CD3+ cells, and 100% (P ≤ .001) reduction in
CD8+ cells infiltrating leaflets. The adventitia showed a
100% (P ≤ .001) reduction in ED1+ cells, 100% (P = .002)
reduction in CD3+ cells, and 100% (P ≤ .001) reduction in
CD8+ cellular infiltration in allograft recipients treated with
cyclosporine compared with untreated recipients.
Short-term therapy (7 days) versus daily therapy with
cyclosporine was evaluated at 4 weeks and compared with
results in syngeneic controls (n = 4) and untreated allo-
grafts (n = 4). Daily therapy (10 mg/kg per day) with
cyclosporine (n = 4) (Figure 5, d) inhibited leaflet infiltra-
tion by mononuclear cells and allowed preservation of
leaflet structural integrity resulting in a normal appearing
functional leaflet similar to that seen in syngeneic control
animals (Figure 5, a). In contrast, animals that had received
a 7-day course of cyclosporine and were evaluated at 28
days all showed evidence of leaflet destruction and com-
plete loss of structural integrity (n = 4) (Figure 5, c), simi-
lar to what has previously been described in untreated ani-
mals (Figure 5, b).10,14
Having shown that T lymphocytes and monocytes/
macrophages significantly infiltrate allogeneic leaflets
within 7 days after implantation, we proceeded to evaluate
the mechanism by which these cells gained access to the
implanted tissue. Anti-α4/β2 integrin blockade resulted in
significant reduction in mononuclear cell infiltration
(Figure 1, c), which was then confirmed by immunocyto-
chemistry (Figures 2, 3, and 4). Anti-α4/β2 integrin mAb
blockade resulted in 86% (P = .032) reduction in ED1+
cells, 72% (P ≤ .001) reduction in CD3+ cells, and 91% (P
≤ .001) reduction in CD8+ cells infiltrating leaflets. There
was a 33% (P = .088) reduction in ED1+ cells, 51% 
(P = .023) reduction in CD3+ cells, and 42% (P = .034)
reduction in CD8+ cells infiltrating the adventitia of allo-
graft recipients after this mAb blockade.
Figure 5. Photomicrographs of valve leaflets 28 days after implantation in syngeneic controls (a), untreated allo-
graft recipients (b), allograft recipients treated with daily cyclosporine for 7 days (c), and allograft recipients
treated with daily cyclosporine for 28 days (d). Arrow indicates leaflet. (Original magnification ×200.). 
316 The Journal of Thoracic and Cardiovascular Surgery • August 2001
Discussion
Contrary to solid organ transplantation, which requires
immediate and lifelong immunosuppression, allograft
heart valves remain clinically functional without immuno-
suppression for a number of years before failing.1 To date,
no systematic attempt has been made to evaluate whether
immunosuppression can lead to long-term survival of
viable valve cellular elements in human beings or ani-
mals, despite increasing evidence that allograft heart
valves in both animals and human beings are antigenic
and result in significant donor-specific immune respons-
es.5-11 We14 have recently provided evidence that aortic
valve graft failure in a rat model is immune mediated and
associated with significant infiltration of the leaflet by T
lymphocytes, more particularly CD8+ cytotoxic T lym-
phocytes. On the basis of that evidence, therapeutic strate-
gies aimed at T-cell activation and/or infiltration were
evaluated for their ability to prevent early leaflet infiltra-
tion, which has been associated with subsequent loss of
stromal cells and eventual structural failure of the
leaflet.14,25
In the present study, Lewis rats were treated with an
immunosuppressive regimen consisting of oral cyclosporine
(10 mg/kg per day) aimed specifically at T-cell activation.
This treatment is known to result in long-term survival of
vascularized allogeneic heart and kidney grafts in the rat.26
We have shown that continuous cyclosporine treatment
resulted in a significant reduction in macrophage (ED1+)
and T-cell (CD3+, CD8+) infiltration of leaflets, in addition
to a significant reduction in infiltrating T cells in the adven-
titia early after implantation. This treatment was very effec-
tive in preserving leaflet structural integrity.
The use of cyclosporine has been reported in a series of
patients requiring fresh arterial homograft implantation
for aortoiliac infection and was reported to cause few
complications.27 However, few clinicians have treated
allograft valve recipients with systemic immunosuppres-
sion for extended periods because of the potential mor-
bidity associated with permanent immunosuppression.
Yankah, Wottge, and Muller-Ruchholtz13 suggested that a
short course of cyclosporine (14 days) could arrest allo-
graft valve rejection on the basis of antibody responses.
We therefore evaluated the potential benefit of a short-
course treatment with cyclosporine around the time of
maximal leaflet mononuclear infiltration (day 7) as com-
pared with continuous daily cyclosporine. The present
study is the first to clearly demonstrate that the histologic
integrity of the leaflets is not preserved by a short course
(7 days) of cyclosporine and that complete leaflet destruc-
tion had occurred at 28 days. In contrast, continuous daily
cyclosporine treatment resulted in preserved leaflet struc-
tural integrity (similar to syngeneic grafts) with no signif-
icant mononuclear infiltration for the entire duration of
the study (28 days).
Taken together, these data provide strong evidence that
early valve leaflet failure is immune mediated and depen-
dent on T lymphocytes. Immunosuppression, which targets
primarily T-lymphocyte activation and proliferation, is pro-
tective and maintains valve allograft structural integrity.
These findings support our previously reported evidence
that T lymphocytes mediate valve allograft failure.10,14
Little is known about the mechanisms by which important
immune effector cells gain access to the transplanted tissues,
including allograft valves. Leukocyte function–associated
antigen-1 (LFA-1) (αLβ2), very late activation antigen-4
(VLA4) (α4β1), MAC-1 (αMβ2), and αXβ2 are integrin mol-
ecules composed of an α and β subunit that are used by T cells
and monocytes to infiltrate sites of inflammation.28 The lig-
ands for these integrins are expressed by endothelial cells in
response to injury and activation, such as transplantation, and
include intercellular adhesion molecules 1 and 2 (ICAM-1 and
ICAM-2) and vascular cell adhesion molecule 1 (VCAM-
1).16,17 The importance of CAMs in facilitating organ allograft
rejection is supported by studies that have attempted to block
the interactions between CAMs and their ligands with mAbs29
or with soluble ligands.30 Blocking antibodies to certain
CAMs have been well demonstrated to prolong graft survival
of solid organ grafts such as heart and renal transplants.29,31
On the basis of the above information, a strategy of α4
and β2 blockade was chosen for the current experiments and
should have caused effective blockade of integrins known to
be used by T cells and monocytes. This strategy resulted in
significant reduction in monocyte/macrophage lineage cells
(ED1+) and T lymphocytes (CD3+, CD8+) in allogeneic
leaflets 7 days after implantation as compared with untreat-
ed allografted recipients.10,14 In contrast, the same blockade
was unable to reduce monocyte/macrophage infiltration of
the adventitia of the graft and resulted in only moderate
reduction in T-cell infiltration of the adventitia. These find-
ings suggest different mechanisms of trafficking of effector
cells to leaflet tissue versus the adventitia. CAMs may also
have important co-stimulatory roles, which were not specif-
ically assessed in this study.28 However, the half-life of anti-
α4/β2 mAb therapy is relatively short and requires repeated
therapy such that no attempts were made to pursue treat-
ment to 28 days. Instead, the information obtained from our
CAM blockade experiments focused on mechanisms of
leukocyte infiltration after transplantation rather than thera-
py, something not previously evaluated by others.
In summary, we have provided evidence that immune
effector cell trafficking to allogeneic valve leaflets after
implantation appears to occur via α4 and/or β2 integrin
pathways. We have also demonstrated that continuous
daily cyclosporine treatment of recipients can result in
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inhibition of allograft valve infiltration and structural
failure.
The development of methods to prolong the durability of
allograft valves would have enormous clinical implications,
especially for young people. Our findings suggest that it
may be possible to use recipient immune modulation to
maintain viable allografts that would lead to lifelong valve
function free of complications. This has been the goal of
cardiac surgeons for the past 40 years. The therapeutic
approaches we are proposing may not protect valve leaflets
indefinitely from cellular loss but may reduce the immune
infiltration observed early after implantation. It is possible
that attenuating this immune attack may lead to better
preservation of the valve structural elements and thus pro-
long the survival of a functional, if not cellular, allograft
valve.
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